Previous 10 | Next 10 |
Ribbon Cutting to be Led by Patient Advocacy Organizations, Caregivers, and Key Stakeholders Largest and First Centralized, Scalable, State-of-the-Art Facility with the Potential to Manufacture TIL Cell Therapies for Thousands of Cancer Patients Annually SAN CARLOS, Calif....
First Patient Infused with TIL Cell Therapy Manufactured at iCTC SAN CARLOS, Calif., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyt...
Shares of biopharma company Iovance (NASDAQ: IOVA) are poised to end Wednesday's trading session almost 11% higher than Tuesday's close, following an encouraging observation from investment analytics outfit Truist. Namely, the odds of an approval of one of its drug prospects seeming...
MaxCyte has become the go-to partner for biotech companies using non-viral cell engineering, aided by its proprietary patented flow electroporation technology. The company has a scalable (licenses and SPLs) business model with recurring revenues. Milestone and royalty payments (at 100...
Start Time: 16:30 End Time: 17:12 Iovance Biotherapeutics, Inc. (IOVA) Q2 2021 Earnings Conference Call August 05, 2021, 16:30 PM ET Company Participants Frederick Vogt - Interim President and CEO Igor Bilinsky - COO Jim Zigler - SVP, Commercial Friedrich Finckenstein - CMO Jean-Marc Bellemin...
Iovance Biotherapeutics (NASDAQ:IOVA): Q2 GAAP EPS of -$0.53 misses by $0.02. Cash position of $708.7 million on June 30, 2021 is expected to be sufficient well into 2023. Press Release For further details see: Iovance Biotherapeutics EPS misses by $0.02
SAN CARLOS, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), today reported second quart...
SAN CARLOS, Calif., July 19, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its second quarter financial results on Thursday, August 5, 2021. Management will host a c...
janiecbros/E+ via Getty Images Biotech M&A is poised to heat up again as shares of the SPDR S&P Biotech’s (XBI) have fallen about 25% from their February highs, according to Jefferies. Biotech deals may pick up after a 3-6 month of a large "drawdown" and as prices "normalize" f...
Shares of Iovance Biotherapeutics (NASDAQ: IOVA) gained 40.1% last month, according to numbers from S&P Global Market Intelligence . The move, largely driven by an update on a key clinical trial, reverses a downtrend that had been underway since February. Iovance Biother...
News, Short Squeeze, Breakout and More Instantly...
Iovance Biotherapeutics Inc. Company Name:
IOVA Stock Symbol:
NASDAQ Market:
Iovance Biotherapeutics Inc. Website:
2024-07-26 10:45:04 ET Pacific Biosciences of California Inc (PACB) PACB is trading UP for the last 5 days, and it at trading at $2.10 with volume of 3,952,245 and a one day change of $0.19 (9.97%). Pacific Biosciences of California Inc has a 52-week low of 1.16 and a 52-week high o...
2024-07-14 05:45:00 ET Biotech stocks like Iovance Biotherapeutics (NASDAQ: IOVA) often look appealing because they could experience enormous growth in relatively short periods of time. Plus, over the long term, successful biotech companies have the opportunity to blossom into large...